CD8A and hepatocellular carcinoma: Combining zoledronic acid with anti-PD-L1 therapy reduced PD-L1+ TAM infiltration and alleviated CD8+ T cell suppression, providing a potential strategy to enhance the efficacy of anti-PD-L1 therapy in HCC [107].